Prevalence of HPV (Human Papilloma Virus) and HPV Vaccination Among Victims of Sexual Violence

Launched by CENTRE HOSPITALIER UNIVERSITAIRE SAINT PIERRE · Feb 12, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the presence of Human Papilloma Virus (HPV) among women who have experienced sexual violence, specifically those admitted to the Sexual Assault Care Center in Brussels. The researchers want to find out how common HPV infections are in these women, especially looking at those who have received the HPV vaccine compared to those who have not. This study aims to help improve care and prevention strategies for women in similar situations.

To participate in this trial, women must be over 15 years old, who have been admitted for rape and can communicate in French, Dutch, or English. Unfortunately, tourists or those who will not be in Belgium for at least a year after their first test cannot join. Participants will be asked to provide consent and will undergo testing for HPV. The findings from this study could provide valuable insights into HPV and its impact on women who have faced sexual violence.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • women over 15 years admitted for rape speaking in french, dutch or english (and therefore able to sign an inform consent in french, dutch or english)
• Exclusion Criteria:
• • tourist or other people who will not in belgium one year after their first test